Invesco Ltd. Hutchmed (China) LTD Transaction History

Invesco Ltd.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$8.63 - $15.52 $16,871 - $30,341	-1,955 Reduced 13.84%	12,174 $108,000
Q2 2022 Aug 15, 2022	SELL	$8.59 - $20.77 $24,722 - $59,776	-2,878 Reduced 16.92%	14,129 $178,000
Q1 2022 May 16, 2022	BUY	$15.52 - $35.65 $40,491 - $93,010	2,609 Added 18.12%	17,007 $322,000
Q4 2021 Feb 14, 2022	SELL	$28.89 - $35.33 $23,603 - $28,864	-817 Reduced 5.37%	14,398 $505,000
Q3 2021 Nov 15, 2021	BUY	$35.66 - $42.94 $129,053 - $155,399	3,619 Added 31.21%	15,215 $557,000
Q2 2021 Aug 17, 2021	BUY	$23.7 - $39.27 $274,825 - $455,374	11,596 New	11,596 $455,000
Q2 2020 Aug 14, 2020	SELL	$17.65 - $28.05 $64 Million - $102 Million	-3,628,145 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$15.19 - $29.51 $1.12 Million - $2.18 Million	-73,713 Reduced 1.99%	3,628,145 $64.8 Million
Q4 2019 Feb 14, 2020	SELL	$17.17 - $25.95 $40,229 - $60,800	-2,343 Reduced 0.06%	3,701,858 $92.8 Million
Q3 2019 Nov 14, 2019	BUY	$17.84 - $22.69 $5,905 - $7,510	331 Added 0.01%	3,704,201 $66.1 Million
Q2 2019 Aug 14, 2019	BUY	$22.0 - $31.78 $81.5 Million - $118 Million	3,703,870 New	3,703,870 $81.5 Million

6.88M

6.2K

1.1K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $2.47B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

Stay updated on Invesco Ltd. with notifications on news.